Our portfolio

Filter Close filters

Displaying 1 - 55 of 55 results

Filter portfolio

Showing 1 - 55 of 55 results

Partners beginning with A
- accuRx
- accuRx
  - Stages:that accuRx support
    
    Venture Growth
  - Sector:that accuRx support
    
    Technology
  About accuRx
  
  accuRx is one of the UK’s fastest-growing healthtech startups, building a communication platform to join up all healthcare communication around the patient to help the NHS deliver more informed care. Founded in 2016, its mission is to change lives by bringing patients and their healthcare teams together. It allows existing health and care systems to deliver technology-enabled care, beginning with the National Health Service (NHS) in the UK. accuRx’s vision is that anyone involved in a patient’s care can communicate with each other. accuRx is now used by 98% of GP practices and a number of secondary care providers.
  
  View website
- Abingworth
- Abingworth
  - Stages:that Abingworth support
    
    Venture
  - Sector:that Abingworth support
    
    Life Sciences
  About Abingworth
  
  Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 170 life science companies, leading to 44 M&As and 69 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.
  
  View website
- Active Partners
- Active Partners
  - Stages:that Active Partners support
    
    Venture Growth
  About Active Partners
  
  Founded in 2004, Active Partners invests in world-class consumer brands, partnering with passionate, innovative founders to build iconic global businesses. Active Partners takes a specialist approach to funding authentic challenger and high-growth sub-sector brands. The firm has invested in a number of hugely successful businesses, including Caravan, CHIK’N, Context, Cubitts, Evans Cycles, Finisterre, The Fold, Honest Burgers, LEON, Northern Monk, Rapha, Secret Cinema, Soho House, Taylor & Hart, TravelLocal and WhoCanFixMyCar.com. For more information, visit the Active Partners website at https://active.partners/
  
  View website
- Advent Life Sciences
- Advent Life Sciences
  - Stages:that Advent Life Sciences support
    
    Venture
  - Sector:that Advent Life Sciences support
    
    Life Sciences
  About Advent Life Sciences
  
  Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of experienced professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe and is particularly focused on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France. For more information, please visit adventls.com
  
  View website
- Alpina Partners
- Alpina Partners
  - Stages:that Alpina Partners support
    
    Venture
  - Sector:that Alpina Partners support
    
    Consumer Goods & Services
    
    Technology
  View website
- Amadeus Capital
- Amadeus Capital
  - Stages:that Amadeus Capital support
    
    Venture Growth
  - Sector:that Amadeus Capital support
    
    Agriculture, Forestry and Fishing
    
    Health & Social Care
    
    Information and Communication
    
    Professional, Scientific and Technical Activities
    
    Technology
  About Amadeus Capital Partners
  
  Amadeus Capital Partners is a global technology investor. Since 1997, the firm has raised over $1bn for investment and used it to back over 170 companies. With vast experience and a great network, Amadeus’ team of investors and entrepreneurs share a passion for the transformative power of technology.
  
  Pioneering businesses we’ve backed include cyber security vendor ForeScout (NASDAQ:FSCT); Graphcore, innovators in intelligent microprocessors; IVF genetic testing company, Igenomix; the first single-chip Bluetooth solution, CSR (acquired by Qualcomm); IndiaMART, the B2B online marketplace (NSE: INDIAMART) and speech recognition company VocalIQ (acquired by Apple).
  
  View website
- Atlantic Bridge
- Atlantic Bridge
  - Stages:that Atlantic Bridge support
    
    Venture
  - Sector:that Atlantic Bridge support
    
    Information and Communication
    
    Technology
  About Atlantic Bridge
  
  Atlantic Bridge Capital is a Global Technology Fund with over €400 million of assets under management across four Funds, investing in technology companies in Europe. We have offices and staff based in London, Dublin, Silicon Valley, Beijing & Hong Kong.
  
  The Fund is focused on investing primarily at the expansion capital and growth equity stages in companies that have started to scale in revenues with a proven business model with evidence of market uptake and customer adoption. Atlantic Bridge has developed a unique and differentiated strategy which focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale up of technology companies in the US and Chinese markets. This approach is highly differentiated and has delivered strong performance results to date. The team has a thirty year operating history working together in technology as entrepreneurs and investors with over $7 billion in exits, having raised four successful technology funds.
  
  View website
- Atomico
- Atomico
  - Stages:that Atomico support
    
    Venture
  - Sector:that Atomico support
    
    Other
  About Atomico
  
  Atomico is a London based venture capital firm partnering with ambitious mission driven European founders at Series A and beyond, leveraging deep operational experience to supercharge their growth. Founded in 2006, Atomico has partnered with over 100 ambitious teams – including those at Supercell, Graphcore, Omio, Klarna, Lilium, MessageBird, Gympass and The Climate Corporation. Atomico’s team of founders, investors and operational leaders have been responsible for global expansion, hiring and marketing at companies from Skype, Google and Twitter to Uber and Spotify. The firm currently has $2.7B in assets under management.
  
  View website
Partners beginning with B
- Balderton Capital
- Balderton Capital
  - Stages:that Balderton Capital support
    
    Venture
  - Sector:that Balderton Capital support
    
    Technology
  About Balderton Capital
  Balderton Capital is Europe’s largest early stage venture capital investor, focused on European technology companies at Series A. Based in London, the firm manages $2.6bn and invests in entrepreneurs building globally ambitious businesses. Balderton’s Partners and advisory team include the founders and operational leaders of multi-billion dollar companies including Business Objects, Dropbox, Uber and Autonomy. Previous investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Sunrise (Microsoft) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of 76 companies are: Aircall, Carwow, Citymapper, Contentful, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Prodigy Finance, Recorded Future, Revolut, ROLI, SOPHiA Genetics, Talend (NASDAQ: TLND), Vestiaire Collective, and Vivino. For more see balderton.com or follow @balderton.
  This year the firm has looked at more than 2,000 startups, from which it has made 10 investments in five countries since March, including Luno, Hiya and SOPHiA Genetics. Balderton’s previous fund (Fund V) has seen a range of category leaders such as Nutmeg, Revolut, Prodigy Finance, Aircall, Carwow, and Frontier Car Group emerge.
  A small team with entrepreneurial roots, Balderton’s partners have between them founded companies that went on to become multi-billion dollar businesses, and worked in the engine rooms of some of the world’s best-known tech brands – including Uber and Dropbox. They have backgrounds and deep networks in Silicon Valley and beyond, and have returned to Europe to play their part in building businesses which will fuel economic growth, jobs and opportunity.
  
  View website
Partners beginning with C
- Cambridge Innovation Capital
- Cambridge Innovation Capital
  - Stages:that Cambridge Innovation Capital support
    
    Venture
  - Sector:that Cambridge Innovation Capital support
    
    Life Sciences
    
    Technology
  About Cambridge Innovation Capital
  
  Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category-leading deep tech and life sciences companies. CIC currently manages in excess of £0.5 billion and has invested in around 40 companies. CIC is a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups.
  
  Cambridge Innovation Capital Manager Limited (FRN:918898) is authorised and regulated by the Financial Conduct Authority. For more information, please visit www.cic.vc or follow on Twitter at @CIC_vc and LinkedIn.
  
  View website
- CloudNC
- CloudNC
  - Stages:that CloudNC support
    
    Venture Growth
  - Sector:that CloudNC support
    
    Technology
  About CloudNC
  
  CloudNC develops advanced software, tested and developed in its own facility, that enables factories to autonomously manufacture more products, more reliably, faster, and with less waste than current processes. The company is seeking to democratise production through its unique, full-stack factory in Essex, United Kingdom, where the software is continuously iterated to achieve full manufacturing autonomy. The company, founded in 2015, consists of a world-class team combining expertise in computer science and physical manufacturing, alongside Autodesk and Lockheed Martin as strategic partners helping to make CloudNC’s solutions available to factories around the world as a software product.
  
  View website
- Crane
- Crane
  - Stages:that Crane support
    
    Venture
  - Sector:that Crane support
    
    Technology
  About Crane Venture Partners
  
  Crane Venture Partners was founded in 2015 and raised $90 million for its first fund in 2019 and $140 million in its second fund in 2022. The firm focuses on early-stage founders building the platforms and tools that will become tomorrow’s software infrastructure across industries.
  
  Crane’s partners work as extended members of founders’ teams, particularly in the areas of marketing, sales and customer success. With more than 50 focused portfolio companies, Crane is one of the deepest specialist funds in Europe. For more information, please visit: https://crane.vc/
  
  View website
Partners beginning with D
- Dawn Capital
- Dawn Capital
  - Stages:that Dawn Capital support
    
    Venture Growth
  About Dawn
  
  Dawn Capital (“Dawn”) is the largest VC fund dedicated to B2B software and B2B fintech start-ups across Europe. Dawn invests from Series A onwards, backing companies that develop world-leading offerings with unbeatable economics. Currently investing out of its third fund of $235 million, Dawn offers ambitious founders operational and financial support to deliver exceptional value growth. Dawn portfolio companies include Mimecast (NASDAQ: MIME with $2.7 market cap), iZettle (sold to PayPal for $2.2BN cash), Collibra, Showpad, Dataiku, Templafy, Quantexa and Garrison, with many others looking to join their ranks.
  
  View website
- Dementia Discovery Fund
- Dementia Discovery Fund
  - Stages:that Dementia Discovery Fund support
    
    Venture
  - Sector:that Dementia Discovery Fund support
    
    Health & Social Care
    
    Life Sciences
  View website
Partners beginning with E
- Epsilogen
- Epsilogen
  - Stages:that Epsilogen support
    
    Venture Growth
  - Sector:that Epsilogen support
    
    Life Sciences
  About Epsilogen
  
  Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
  
  Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity also seen. The company is also developing a proprietary IGEG^TM antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
  
  Epsilogen began operations in 2017 as a spin out of King’s College London utilising the world class IgE expertise of Professor Sophia Karagiannis. Initial capital was provided by founding investor Epidarex Capital.
  
  View website
- ETF Partners
- ETF Partners
  - Stages:that ETF Partners support
    
    Venture Growth
  - Sector:that ETF Partners support
    
    Technology
  About ETF Partners
  
  ETF Partners supports talented entrepreneurs and management teams with investment capital and experience. Our funds come from institutional investors, global corporations and family offices. We create value by investing in technology companies that make a difference. We call it ‘sustainability through innovation’.
  
  For more insight into ETF Partners’ view on Sustainability through Innovation, please read our investor briefings.
  
  View website
- Eurazeo
- Eurazeo
  - Stages:that Eurazeo support
    
    Venture
  - Sector:that Eurazeo support
    
    Consumer Goods & Services
    
    Financial and Insurance Services
    
    Life Sciences
    
    Technology
  View website
- Evolution Equity Partners
- Evolution Equity Partners
  - Stages:that Evolution Equity Partners support
    
    Venture Growth
  - Sector:that Evolution Equity Partners support
    
    Technology
  About Evolution Equity
  
  Evolution Equity Partners, based in London, Palo Alto, New York City and Zurich invests in fast growing technology companies in North America and Europe helping exceptional entrepreneurs develop market leading companies. The firm has a focus on Cybersecurity and Enterprise Software and its partners have been involved as founders, investors and as senior operating executives in leading software companies around the world.
  For more information, please visit www.evolutionequity.com or connect with on LinkedIn and Twitter @evolutionequity.
  
  View website
Partners beginning with F
- FPE Capital
- FPE Capital
  - Stages:that FPE Capital support
    
    Venture Growth
  - Sector:that FPE Capital support
    
    Technology
  About FPE Capital
  FPE is a growth private equity investor specialising in lower mid-market UK based companies with advantaged business models that offer significant growth potential in large markets that are undergoing structural change. FPE was established as an independent investor by its management team in March 2016. It is authorised and regulated by the Financial Conduct Authority.
  
  View website
- Frog Capital
- Frog Capital
  - Stages:that Frog Capital support
    
    Venture Growth
  - Sector:that Frog Capital support
    
    Technology
  About Frog Capital
  
  Frog Capital is a London-based European investment firm, specialising in growth capital for technology-driven businesses. With a highly focused and selective approach, Frog leads or partners on investments of up to €20m to back ambitious teams that are scaling high-growth businesses with proven models.
  
  Having had three successful exits from its Frog Capital I fund, Frog Capital has raised Frog Capital II from a mix of 14 institutional and family office investors.
  
  View website
Partners beginning with G
- Grey Wolf Therapeutics
- Grey Wolf Therapeutics
  - Stages:that Grey Wolf Therapeutics support
    
    Venture
  - Sector:that Grey Wolf Therapeutics support
    
    Life Sciences
  About Grey Wolf Therapeutics
  Grey Wolf Therapeutics is a UK- and Australian-based drug discovery and development biotechnology company spearheading a new therapeutic approach in immuno-oncology. The company’s first-of-its-kind immuno-oncology approach is centered on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 or ERAP2), which play a key role in the antigen presentation pathway. Inhibiting ERAP1 or ERAP2 generates novel neoantigens and upregulates certain other neoantigens, resulting in the mobilisation of an entirely novel T cell response against the tumour that increases tumour visibility where current therapies are ineffective, and bypasses the challenge faced by current immunotherapy when once anti-tumourigenic T cells become irreversibly exhausted and hence ineffective. Based on this approach, the company is developing a portfolio of potentially first-in-class small molecules that inhibit ERAP1 or ERAP2. The company’s lead development candidate, GRWD5769, is a potent and selective ERAP1 inhibitor that elicits a powerful and differentiated immune response against the tumour and is anticipated to enter the clinic in the first half of 2023. A second program, focused on ERAP2 inhibition, is advancing through the discovery process. With the creation of novel neoantigens, the company is leveraging its leadership in neoantigen creation to unlock entirely novel cancer antigens that can be targeted with MHC Class I directed therapies, such as soluble T cell receptor (TCR) and TCR mimic bispecifics.For more information, please visit gwt.bio.
  
  View website
Partners beginning with H
- Hoxton Ventures
- Hoxton Ventures
  - Stages:that Hoxton Ventures support
    
    Venture
  - Sector:that Hoxton Ventures support
    
    Technology
  About Hoxton Ventures
  
  Hoxton Ventures is an early stage venture capital firm investing in European technology startups that can scale into large, global winners. It focuses on startups that either disrupt existing industries or invent entirely new market categories. It was an early investor in Babylon Health, Darktrace and Deliveroo, and its portfolio companies have grown to an aggregate value of over $7 billion. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed and Series A stage companies, and follows its capital through the life of the company. For more information please visit www.hoxtonventures.com.
  
  View website
Partners beginning with I
- Iceotope
- Iceotope
  - Stages:that Iceotope support
    
    Venture Growth
  - Sector:that Iceotope support
    
    Technology
  About Iceotope
  
  Iceotope’s chassis level precision immersion cooling solutions are engineered to cool the whole IT stack, in every use case, from Hyperscale to the Extreme Edge. By removing the need for fans and air-cooling infrastructure, Iceotope’s technologies operate in near silence — bringing game-changing reduction in energy and water consumption, and significant cost reductions in the design, build and operation of data centres and HPC solutions. For more information, visit: www.iceotope.com
  
  View website
- IQ Capital
- IQ Capital
  - Stages:that IQ Capital support
    
    Venture
  - Sector:that IQ Capital support
    
    Technology
  About IQ Capital Partners
  
  IQ Capital Partners is an Early Growth Venture Capital firm established to address certain imbalances in the traditional European venture capital model, and focuses on creating a strong and effective collaboration with CEOs and other investors.
  
  Our approach creates a solid collaboration with founders and other investors through the model of investing alongside sector experts and entrepreneurs – ‘ IQ Angels’ – who have previously managed and achieved significant exit success with innovative technology companies. These IQ Angels, endorsed by the portfolio companies, work in partnership with IQ Capital Partners and the company founders to provide connections and constructive strategic advice throughout the various growth phase hurdles and to provide a great sounding board for CEOs through open discussion and sharing of their previous experiences.
  
  The fund invests between £1-5m in innovative, fast-growing technology and B2B companies, including SaaS and PaaS, IoT, digital media, enterprise software, robotics and med-tech. The team, Max Bautin, Ed Stacey and Kerry Baldwin, has delivered significant returns to investors since 1997, including Autonomy (IPO), Sirigen (BD), Phonetic Arts (Google), KVS (Veritas), JCP (Sun), 365Corp (IPO) and WhereonEarth (Yahoo) and draws upon a diverse range of investment experience to generate excellent returns to investors.
  
  We are always open to building relationships with new ‘IQ Angels’ who have a deep understanding of a specific technology sector, gained through the experience of growing and exiting successful businesses in that sector, who are prepared to invest in early growth technology companies, and also prepared to take an active role and a collaborative approach. IQ Capital invests across the UK and has offices located in Cambridge and London.
  
  View website
Partners beginning with K
- Kennet
- Kennet
  - Stages:that Kennet support
    
    Venture Growth
  - Sector:that Kennet support
    
    Technology
  About Kennet Partners
  Kennet is a leading international growth equity firm that invests in high-growth companies in Europe and North America. With offices in London and Silicon Valley, the firm supports entrepreneurial technology businesses with expansion capital to accelerate growth and build exceptional shareholder value. Kennet is an experienced investor with approximately $1 billion of cumulative funds under management.
  
  View website
- Kester Capital
- Kester Capital
  - Stages:that Kester Capital support
    
    Venture
  - Sector:that Kester Capital support
    
    Consumer Goods & Services
    
    Financial and Insurance Services
    
    Health & Social Care
    
    Information and Communication
    
    Technology
  View website
- Kindred
- Kindred
  - Stages:that Kindred support
    
    Venture
  - Sector:that Kindred support
    
    Technology
  About Kindred Capital
  
  Kindred Capital has £161m under management. It recently raised a £81m second fund and has finished making initial investments from its first fund, which was £80m. Kindred Capital is a seed and early stage venture capital investor, focusing on European technology companies. Based in London, invests in entrepreneurs building globally ambitious businesses.
  
  Kindred’s portfolio includes Five, Paddle, LabGenius, Pollen, Disperse and Farewill. Kindred’s Equitable Venture model is currently predicted to return over £5m to portfolio founders.
  
  View website
Partners beginning with M
- Microbiotica
- Microbiotica
  - Stages:that Microbiotica support
    
    Venture
  - Sector:that Microbiotica support
    
    Life Sciences
  About Microbiotica
  Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.
  Consisting of the leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD and it has established major clinical and academic partnerships in these areas.
  Spun out of the Sanger Institute in 2016, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica’s investor syndicate includes British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners, and Tencent.
  
  View website
- Molten Ventures Plc
- Molten Ventures Plc
  - Stages:that Molten Ventures Plc support
    
    Venture
  - Sector:that Molten Ventures Plc support
    
    Health & Social Care
    
    Information and Communication
    
    Technology
  View website
- MVM Partners
- MVM Partners
  - Stages:that MVM Partners support
    
    Venture
  - Sector:that MVM Partners support
    
    Health & Social Care
    
    Life Sciences
    
    Technology
  View website
Partners beginning with N
- Nauta Capital
- Nauta Capital
  - Stages:that Nauta Capital support
    
    Venture
  - Sector:that Nauta Capital support
    
    Technology
  About Nauta Capital
  
  Nauta Capital is a pan-European Venture Capital firm investing in early-stage technology companies, with offices in London, Barcelona. and Berlin. With over half a billion assets under management and a team of 24 people, Nauta Capital is one of Europe’s largest B2B focused VCs.
  
  As a sector-agnostic investor, Nauta’s main areas of interest include B2B SaaS solutions with strong network effects, vertically focused enterprise tech transforming large industries as well as those leveraging deep-tech applications to solve challenges faced by large enterprises. Nauta has backed more than 60 companies across Europe and exited 12.
  
  View website
- Northern Gritstone
- Northern Gritstone
  - Stages:that Northern Gritstone support
    
    Venture
  - Sector:that Northern Gritstone support
    
    Life Sciences
    
    Technology
  Northern Gritstone is a ground-breaking new investment company based in the north of England, founded by the Universities of Leeds, Manchester and Sheffield, three of the UK’s leading educational research establishments. It intends to be one of the largest investors into academic spin-outs and IP-rich businesses in the UK dedicated to financing companies in some of the UK’s fastest growing sectors such as advanced materials, energy, health technology and cognitive computation.
  
  Visit website
- Notion Capital
- Notion Capital
  - Stages:that Notion Capital support
    
    Venture
  - Sector:that Notion Capital support
    
    Technology
  View website
- Nucleome Therapeutics
- Nucleome Therapeutics
  - Stages:that Nucleome Therapeutics support
    
    Venture
  - Sector:that Nucleome Therapeutics support
    
    Life Sciences
  About Nucleome Therapeutics
  Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit nucleome.com.
  
  View website
Partners beginning with O
- OMass Therapeutics
- OMass Therapeutics
  - Stages:that OMass Therapeutics support
    
    Venture Growth
  - Sector:that OMass Therapeutics support
    
    Life Sciences
  About OMass Therapeutics
  
  OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, therapeutics that target solute carriers, complex-bound proteins, and GPCRs.
  
  Headquartered in Oxford, UK, OMass has raised over $150M (£119M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
  
  To learn more, please visit www.omass.com. Follow us on LinkedIn and Twitter.
  
  Visit website
- Oxford Quantum Circuits
- Oxford Quantum Circuits
  - Stages:that Oxford Quantum Circuits support
    
    Venture
  - Sector:that Oxford Quantum Circuits support
    
    Technology
  About Oxford Quantum Circuits
  OQC is Europe’s leading quantum computing company. We bring quantum to our customers’ fingertips and enable them to make breakthrough discoveries. Our quantum computers are available via private cloud and on Amazon Braket.
  
  View website
- Oxx
- Oxx
  - Sector:that Oxx support
    
    Technology
  About Oxx
  
  Oxx invests growth capital in European B2B scaleup stage SaaS (Software-as-a-Service) companies with strong commercial traction. With team members in London and Stockholm, Richard Anton and Mikael Johnsson launched Oxx after departing Amadeus Capital in 2017. They are joined by Robert Easton, who was previously head of several Carlyle Group funds, as Senior Adviser. Previous Oxx companies include Forescout (NASDAQ: FSCT), which Richard invested in at Amadeus and continues to manage at Oxx. ForeScout completed its IPO in October 2017.
  
  Oxx’s current portfolio companies are:
  
  Apica– Performance monitoring for companies with complex IT infrastructures
  
  Funnel– Automated performance reporting and intelligence for businesses
  
  ThinkTank– Cloud-based stakeholder engagement system for enterprises
  
  Zift– Channel sales, marketing and operations technology
  View website
Partners beginning with P
- Panoramic Growth Equity
- Panoramic Growth Equity
  - Stages:that Panoramic Growth Equity support
    
    Venture
  - Sector:that Panoramic Growth Equity support
    
    Other
  View website
- Paragraf
- Paragraf
  - Stages:that Paragraf support
    
    Venture Growth
  - Sector:that Paragraf support
    
    Technology
  About Paragraf
  
  Based near Cambridge, UK, and building on significant know-how and IP, Paragraf has developed atom-layer-thick two-dimensional materials, with a focus on graphene. Through its growing IP portfolio, Paragraf is applying these materials to a range of advanced medical, electronic and energy devices to benefit society.
  
  View website
- Partech
- Partech
  - Stages:that Partech support
    
    Venture
  - Sector:that Partech support
    
    Technology
  About Partech
  
  Born in San Francisco and Paris, Partech is one of the most active tech investors in the world, bringing together capital, operational experience, and strategic support for entrepreneurs at seed, venture and growth stages. The current portfolio includes 200+ companies in more than 30 countries, of which 12 are valued at more than $1b: Alan, Bolt, Cazoo, Jellysmack, Made.com, ManoMano, People.ai, Rohlik, Sorare, Toss, Wave, Xendit
  
  View website
- Passion Capital
- Passion Capital
  - Stages:that Passion Capital support
    
    Venture
  - Sector:that Passion Capital support
    
    Technology
  About Passion Capital
  
  Passion Capital, (@passioncapital) is one of the premier early stage venture capital funds in Europe. Established in 2011 and based in London, the managing partners Eileen Burbidge, Robert Dighero and Stefan Glaenzer have more than 50 years’ collective experience in entrepreneurial, founding and executive operational roles at tech firms. The three of them were personally involved in four of the largest European exits of the year over the last ten years and pride themselves on the strength of their portfolio company founders.
  
  View website
- Perspectum
- Perspectum
  - Stages:that Perspectum support
    
    Venture Growth
  - Sector:that Perspectum support
    
    Life Sciences
  About Perspectum
  
  Perspectum, a global medical technology company with offices in the UK, the US, Portugal and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. For additional information please visit www.perspectum.com and LinkedIn.
  
  https://www.perspectum.com/
- PragmatIC
- PragmatIC
  - Stages:that PragmatIC support
    
    Venture Growth
  - Sector:that PragmatIC support
    
    Technology
  About PragmatIC Semiconductor
  PragmatIC Semiconductor is a world leader in ultra-low-cost flexible electronics. Its unique technology platform enables innovators to create novel solutions to everyday problems that are beyond the scope of conventional electronics. Its flexible integrated circuits (FlexICs) are thinner than a human hair and extend proven applications such as RFID and NFC into mass market use cases, enabling the potential for trillions of smart objects that can engage with consumers and their environments. PragmatIC is headquartered in Cambridge, UK, with manufacturing operations in the North East.
  
  https://www.pragmaticsemi.com/
- Prime Ventures
- Prime Ventures
  - Stages:that Prime Ventures support
    
    Venture Growth
  - Sector:that Prime Ventures support
    
    Consumer Goods & Services
    
    Technology
  View website
- Proximie
- Proximie
  - Stages:that Proximie support
    
    Venture Growth
  - Sector:that Proximie support
    
    Life Sciences
  About Proximie
  Proximie is a global health technology platform focused on digitizing operating and diagnostic rooms. Proximie’s mission is to save lives by sharing the world’s best clinical practice. Every Proximie procedure can be recorded, analysed and leveraged for future use to help inform best practice.
  By connecting operating rooms globally, Proximie is creating a rich, insightful data set which naturally feeds best practices into the entire healthcare ecosystem, delivering global connected surgical care.
  Founded by Dr Nadine Hachach-Haram, Proximie has now conducted tens of thousands of surgical procedures – in every speciality – and been deployed in over 500 hospitals in across 100 countries in five continents.
  Proximie has contracts with over 35 major medical device companies – with access to 90% of operating rooms and diagnostic suites in the UK, US, and EU.
  
  View website
Partners beginning with Q
- Quantexa
- Quantexa
  - Stages:that Quantexa support
    
    Venture Growth
  - Sector:that Quantexa support
    
    Technology
  About Quantexa
  Quantexa is a contextual decision intelligence software company that empowers organisations to drive better decisions from their data. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risk and new opportunities by providing a contextual view of internal and external data in a single place. It solves major challenges across financial crime, customer intelligence, credit risk, fraud and throughout the customer lifecycle.
  The Quantexa platform enhances performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has over 250 employees and thousands of users working with billions of transactions and data points across the world. It has offices in London, New York, Boston, Belgium, Toronto, Singapore, Melbourne and Sydney.
  
  View website
- Quell
- Quell
  - Stages:that Quell support
    
    Venture Growth
  - Sector:that Quell support
    
    Life Sciences
  View website
Partners beginning with S
- Scottish Equity Partners
- Scottish Equity Partners
  - Stages:that Scottish Equity Partners support
    
    Venture
  - Sector:that Scottish Equity Partners support
    
    Information and Communication
    
    Technology
  About Scottish Equity Partners
  
  Scottish Equity Partners (SEP) is a leading UK venture capital firm. Operating from offices in London, Glasgow and Edinburgh, SEP makes equity investments of up to £20m in high growth technology companies.
  
  The new fund will be invested in high-growth companies based mainly in the UK, although investments in other European countries will also be targeted.
  
  View website
- Seedcamp
- Seedcamp
  - Stages:that Seedcamp support
    
    Venture
  - Sector:that Seedcamp support
    
    Other
  About Seedcamp
  
  Seedcamp is Europe’s seed fund, investing early in world-class founders attacking large, global markets and solving real problems using technology. The Seedcamp Nation includes over 360 breakout businesses and includes the likes of Hopin, Revolut, UiPath, Transferwise, Pointy (acquired by Google), wefox, Ezra, viz.ai and Stupefix (acquired by GoPro). Seedcamp fast-tracks a founder’s vision through immediate access to smart capital, a lifelong community of support and a global network of some of the world’s best talent.
  
  View website
- SV Health Investors
- SV Health Investors
  - Stages:that SV Health Investors support
    
    Venture
  - Sector:that SV Health Investors support
    
    Life Sciences
  About SV Health Investors
  SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.2B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies with more than 75 of these having achieved successful acquisitions or IPOs.
  Historically, SV managed funds have been diversified across the three sectors. However, the firm’s seventh vintage of core funds is separated into three distinct vehicles; the SV7 Impact Medicine Fund forms and funds early-stage biotechnology companies developing precision medicines, the Growth Fund accelerates growth-stage healthcare services, medical products and digital health companies and the Medtech Convergence Fund specializes in novel medical device and remote-monitoring technologies.
  Alongside their core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia, and the International Biotechnology Trust plc, a publicly-traded investment trust.
  
  View website
Partners beginning with T
- Tenpoint Therapeutics
- Tenpoint Therapeutics
  - Stages:that Tenpoint Therapeutics support
    
    Venture Growth
  - Sector:that Tenpoint Therapeutics support
    
    Life Sciences
  Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision. Tenpoint’s global team is united by our passion for science and our commitment to patients.
  
  https://www.tenpointtherapeutics.com/
- Thought Machine
- Thought Machine
  - Stages:that Thought Machine support
    
    Venture Growth
  - Sector:that Thought Machine support
    
    Technology
  About Thought Machine
  Thought Machine was founded in 2014 with a mission to enable banks to deploy modern systems and move away from the legacy IT platforms that plague the banking industry. We do this through our cloud native core banking platform, Vault. This next generation system has been written from scratch as an entirely cloud native platform. It does not contain a single line of code which is legacy, or pre-cloud.
  Founded by entrepreneur Paul Taylor, Thought Machine’s customers include Lloyds Banking Group, SEB, Standard Chartered and Atom bank. We are currently a team of more than 350 people spread across offices in London and Singapore.
  
  View website
Partners beginning with U
- UCL Technology Fund
- UCL Technology Fund
  - Stages:that UCL Technology Fund support
    
    Venture
  - Sector:that UCL Technology Fund support
    
    Engineering
    
    Life Sciences
    
    Professional, Scientific and Technical Activities
  About UCL Technology Fund and UCL Technology Fund 2
  The UCL Technology Funds are dedicated to investing in intellectual property and commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on the physical and life sciences. The funds support UCL academics in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application.
  The Funds are managed by AlbionVC, one of the largest independent venture capital investors in the UK, in collaboration with UCL Business.
  
  View website
- Ultraleap
- Ultraleap
  - Stages:that Ultraleap support
    
    Venture Growth
  - Sector:that Ultraleap support
    
    Technology
  View website
Partners beginning with W
- Westbridge
- Westbridge
  - Stages:that Westbridge support
    
    Venture
  - Sector:that Westbridge support
    
    Consumer Goods & Services
    
    Technology
  View website

The information has been supplied by each fund manager or company. British Patient Capital makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any such data or information. The information is for information only.

In cases where fund managers have different strategies for different funds, the information refers to the funds to which British Patient Capital has made commitments.

The investment range for funds typically refers to the amount at first investment, not the full amount that may be invested through further funding rounds, or by other investors that may join in a funding round.

For full information see the website terms and conditions.

Beware of scams

Our portfolio

Displaying 1 - 55 of 55 results

Showing 1 - 55 of 55 results

Partners beginning with A

Stages:that accuRx support

Sector:that accuRx support

About accuRx

Stages:that Abingworth support

Sector:that Abingworth support

About Abingworth

Stages:that Active Partners support

About Active Partners

Stages:that Advent Life Sciences support

Sector:that Advent Life Sciences support

About Advent Life Sciences

Stages:that Alpina Partners support

Sector:that Alpina Partners support

Stages:that Amadeus Capital support

Sector:that Amadeus Capital support

About Amadeus Capital Partners

Stages:that Atlantic Bridge support

Sector:that Atlantic Bridge support

About Atlantic Bridge

Stages:that Atomico support

Sector:that Atomico support

About Atomico

Partners beginning with B

Stages:that Balderton Capital support

Sector:that Balderton Capital support

About Balderton Capital

Partners beginning with C

Stages:that Cambridge Innovation Capital support

Sector:that Cambridge Innovation Capital support

About Cambridge Innovation Capital

Stages:that CloudNC support

Sector:that CloudNC support

About CloudNC

Stages:that Crane support

Sector:that Crane support

About Crane Venture Partners

Partners beginning with D

Stages:that Dawn Capital support

About Dawn

Stages:that Dementia Discovery Fund support

Sector:that Dementia Discovery Fund support

Partners beginning with E

Stages:that Epsilogen support

Sector:that Epsilogen support

About Epsilogen

Stages:that ETF Partners support

Sector:that ETF Partners support

About ETF Partners

Stages:that Eurazeo support

Sector:that Eurazeo support

Stages:that Evolution Equity Partners support

Sector:that Evolution Equity Partners support

About Evolution Equity

Partners beginning with F

Stages:that FPE Capital support

Sector:that FPE Capital support

About FPE Capital

Stages:that Frog Capital support

Sector:that Frog Capital support

About Frog Capital

Partners beginning with G

Stages:that Grey Wolf Therapeutics support

Sector:that Grey Wolf Therapeutics support

About Grey Wolf Therapeutics

Partners beginning with H

Stages:that Hoxton Ventures support

Sector:that Hoxton Ventures support

About Hoxton Ventures

Partners beginning with I

Stages:that Iceotope support

Sector:that Iceotope support

About Iceotope

Stages:that IQ Capital support

Sector:that IQ Capital support

About IQ Capital Partners